
1. j clin microbiol. 2014 may;52(5):1511-8. doi: 10.1128/jcm.00100-14. epub 2014 feb
26.

interlaboratory reproducibility proficiency testing within human
papillomavirus cervical cancer screening program catalonia, spain.

ibáñez r(1), félez-sánchez m, godínez jm, guardià c, caballero e, juve r,
combalia n, bellosillo b, cuevas d, moreno-crespi j, pons l, autonell j,
gutierrez c, ordi j, de sanjosé s, bravo ig.

author information: 
(1)infections cancer unit, cancer epidemiology research program, catalan
institute oncology (ico), l'hospitalet de llobregat, barcelona, spain.

in catalonia, screening protocol cervical cancer, including human
papillomavirus (hpv) dna testing using digene hybrid capture 2 (hc2) assay,
was implemented 2006. order monitor interlaboratory reproducibility, a
proficiency testing (pt) survey hpv samples launched 2008. aim 
of study explore repeatability hc2 assay's performance.
participating laboratories provided 20 samples annually, 5 randomly chosen
samples following relative light unit (rlu) intervals: <0.5, 0.5
to 0.99, 1 9.99, ≥10. kappa statistics used determine the
agreement levels original pt readings. nature origin 
of discrepant results calculated bootstrapping. total 946
specimens retested. kappa values 0.91 positive/negative
categorical classification 0.79 four rlu intervals studied. sample
retesting yielded systematically lower rlu values original test
(p<0.005), independently time elapsed two determinations
(median, 53 days), possibly due freeze-thaw cycles. probability a
sample show clinically discrepant results upon retesting function the
rlu value; samples rlu values 0.5 5 interval showed 10.80%
probability yield discrepant results (95% confidence interval [ci], 7.86 to
14.33) compared 0.85% probability samples outside interval (95% ci,
0.17 1.69). globally, hc2 assay shows high interlaboratory concordance. we
have identified differential confidence thresholds suggested guidelines
for interlaboratory pt future, analytical quality assessment hpv dna
detection remains central component screening program cervical
cancer prevention.

doi: 10.1128/jcm.00100-14 
pmcid: pmc3993685
pmid: 24574284  [indexed medline]

